Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Artigo
|
Prophylaxis and treatment of hepatitis B in immunocompromised patientsMarzano, A ; Angelucci, E ; Andreone, P ; Brunetto, M ; Bruno, R ; Burra, P ; Caraceni, P ; Daniele, B ; Di Marco, V ; Fabrizi, F ; Fagiuoli, S ; Grossi, P ; Lampertico, P ; Meliconi, R ; Mangia, A ; Puoti, M ; Raimondo, G ; Smedile, ADigestive and liver disease, 2007-05, Vol.39 (5), p.397-408 [Periódico revisado por pares]Netherlands: Elsevier LtdTexto completo disponível |
|
2 |
Material Type: Artigo
|
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovirPapatheodoridis, George V ; Dalekos, George N ; Yurdaydin, Cihan ; Buti, Maria ; Goulis, John ; Arends, Pauline ; Sypsa, Vana ; Manolakopoulos, Spilios ; Mangia, Giampaolo ; Gatselis, Nikolaos ; Keskın, Onur ; Savvidou, Savvoula ; Hansen, Bettina E ; Papaioannou, Christos ; Galanis, Kostantinos ; Idilman, Ramazan ; Colombo, Massimo ; Esteban, Rafael ; Janssen, Harry L.A ; Lampertico, PietroJournal of hepatology, 2015-02, Vol.62 (2), p.363-370 [Periódico revisado por pares]Netherlands: Elsevier B.VTexto completo disponível |
|
3 |
Material Type: Artigo
|
Chronic viral hepatitis: The histology reportGuido, Maria ; Mangia, Alessandra ; Faa, GavinoDigestive and liver disease, 2011-03, Vol.43, p.S331-S343 [Periódico revisado por pares]Netherlands: Elsevier LtdTexto completo disponível |
|
4 |
Material Type: Artigo
|
Mortality rate and predictors of liver disease damage in histologically diagnosed Nonalcholic Steatohepatitis: a 15 years follow-up cohort studyMangia, A ; Santoro, R ; Piazzolla, V ; Squillante, M.M ; Petruzzellis, D ; Agostinacchio, E ; Guido, MJournal of hepatology, 2017, Vol.66 (1), p.S148-S148 [Periódico revisado por pares]Texto completo disponível |
|
5 |
Material Type: Artigo
|
Prevalence and Clinical Importance of Hepatitis C Virus Genotype 2 K/1B ChimerasSusser, S ; Dietz, J ; Barak, M ; Schlevogt, B ; Daniel, R ; Piazzolla, V ; Passmann, S ; Cornberg, M ; Zuckerman, E ; Mangia, A ; Zeuzem, S ; Sarrazin, CJournal of hepatology, 2016, Vol.64 (2), p.S136-S136 [Periódico revisado por pares]Texto completo disponível |
|
6 |
Material Type: Artigo
|
P1208 PREDICTION OF SEVERE CUTANEOUS REACTION DURING TRIPLE THERAPY IN HCV: VALIDATION OF A GWAS CANDIDATE GENETIC MARKERPalescandolo, E ; Vijgen, L ; Talloen, W ; Colombo, M ; Mangia, A ; Wedemeyer, H ; Demasi, R ; Lonjon-Domanec, I ; Aerssens, JJournal of hepatology, 2014-04, Vol.60 (1), p.S490-S491 [Periódico revisado por pares]Elsevier B.VTexto completo disponível |
|
7 |
Material Type: Artigo
|
IFNL4 polymorphisms predict sustained response and HBsAg clearance in interferon treated HBeAg negative chronic hepatitis B patientsGalmozzi, E ; Lampertico, P ; Facchetti, F ; Invernizzi, F ; Mangia, G ; Vigano, M ; Soffredini, R ; Colombo, MDigestive and liver disease, 2015-02, Vol.47, p.e49-e49 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
|
8 |
Material Type: Artigo
|
815 FACTORS ASSOCIATED WITH INTOLERANCE TO PEGINTERFERON alfa/RIBAVIRIN IN TREATMENT-NAÏVE, CIRRHOTIC/NON-CIRRHOTIC HCV GENOTYPE 1-INFECTED PATIENTS: ANALYSIS OF DATA FROM THE MULTINATIONAL PROPHESYS COHORTSFirpi, R ; Reau, N ; Korner, E ; Hoop, R ; Han, J ; Mangia, A ; Ferenci, P ; Everson, GJournal of hepatology, 2013-04, Vol.58, p.S334-S334 [Periódico revisado por pares]Elsevier B.VTexto completo disponível |
|
9 |
Material Type: Artigo
|
P1220 MODELING PREDICTS CLINICALLY MEANINGFUL SVR RATES IN GENOTYPE 1 TREATMENT-EXPERIENCED PATIENTS BASED ON RESULTS IN GENOTYPE 1 TREATMENT-NAIVE PATIENTS TREATED WITH SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN FOR 12 WEEKSMuir, A ; Nelson, D.R ; Gordon, S.C ; Feld, J.J ; Patel, K ; Lawitz, E ; Sheikh, A.M ; Brainard, D.M ; Symonds, W.T ; McHutchison, J.G ; Bekele, B.N ; Mangia, A ; Gane, E.JJournal of hepatology, 2014-04, Vol.60 (1), p.S495-S495 [Periódico revisado por pares]Elsevier B.VTexto completo disponível |
|
10 |
Material Type: Artigo
|
5 PHASE 3 RANDOMIZED CONTROLLED TRIAL OF ALL-ORAL TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS COMPARED TO 24 WEEKS OF PEG + RIBAVIRIN IN TREATMENT-NAÏVE GT2/3 HCV-INFECTED PATIENTS (FISSION)Gane, E ; Lawitz, E ; Rodriguez-Torres, M ; Gordon, S ; Dvory-Sobol, H ; Arterburn, S ; McNally, J ; Brainard, D.M ; Symonds, W.T ; McHutchison, J.G ; Sheikh, A ; Mangia, AJournal of hepatology, 2013-04, Vol.58, p.S3-S3 [Periódico revisado por pares]Elsevier B.VTexto completo disponível |